Adenocarcinoma

Squamous cell cancer of the anal canal is rare and adenocarcinoma is rarer still, accounting for 10% of all anal cancers.1,2 The 3 types of anal adenocarcinoma are those arising in the anorectum, in the anal glands, and in an anorectal fistula.3

Occurring most proximally is the adenocarcinoma arising from the rectal type of anal mucosa. It appears similar to a rectal adenocarcinoma. The second type of adenocarcinoma arises from the base of the anal glands and may be an adenomatous type of cancer or a squamous variety depending on its cellular origin. The third type arises from a chronic anorectal fistula and may be a well-differentiated mucinous adenocarcinoma.

It is useful to understand the anatomy and histology of the anal canal in order to appreciate the derivation of these tumors. The anal canal is a small but complicated structure (Figure 1). It is 4 cm in length and begins at the anorectal ring, which is formed by the upper edge of the internal anal sphincter and the puborectalis muscle. The canal extends to the anal verge. Distal to this is the perianal skin. The perianal skin extends outward, onto the buttocks for 5 cm.

The histology of the anal canal is intricate and variable. The lining of the proximal canal is mucosal or endodermal, and is composed of a columnar epithelium. The columnar epithelium gradually transitions into a cutaneous or ectodermal squamous epithelium through the anal transition zone (ATZ). The ATZ is 1 cm in length and ends at the dentate line, which is located approximately 2 cm proximal to the anal verge. The dentate line is the remnant of the embryonic proctodeal membrane, or junction of the proctodeum and ectoderm. Distal to the dentate line, the anal epithelium approximates that of skin except that it is non-keratinized and does not contain hair or glandular structures. This area is referred to as the anoderm. At the anal verge, the lining becomes that of true keratinized skin with hair, sebaceous glands, and sweat glands.

The lining of the anal canal proximal to the dentate line is thrown into pleats or columns due to the narrowing size of the canal as it moves distally. The columns, 5 to 15 in number, are termed the columns of Morgagni. At the lower end of each column, and between each column is a small pocket, or anal crypt. These crypts connect to anal glands.

Anal glands begin at the crypt and extend outward. The ducts of the anal glands are lined by a squamous epithelium. This epithelium transitions into a columnar epithelium deep in the gland. Interspersed along the length of this epithelium are mucus-secreting cells, or goblet cells. The glands are involved with the pathogenesis of anorectal abscesses, fistulous disease, and with rarely occurring anal fistula malignancies.

The rectal type of adenocarcinoma looks like a distal colon adenocarcinoma and usually is indistinguishable from a colorectal neoplasm. This is the most common type of anal canal adenocarcinoma. The adenocarcinoma arising in a fistula is a well-differentiated cancer most commonly arising in patients with a chronic anal fistula or perianal disease.

Anal glandular adenocarcinomas commonly arise in the sixth to eighth decades of life.2,3 These tumors may present with signs and symptoms identical to other benign anorectal disorders. In a study of 21 patients by Jensen,4 patients complained of pain, leakage, bleeding, pruritus, prolapse, or weight loss. Exams disclosed induration, an associated abscess or fistula, or a mass. An initial misdiagnosis was common. Patients experienced complaints and symptoms for 18 months before the correct diagnosis was made. Tumors of the anal canal averaged 5 cm in length and those of the perianal area averaged 10 cm in length. Sixty-two patients presented with regional or distant metastases and 20 of 21 patients were dead within 18 months after treatment. These lesions often arise in an extramucosal location and there is no involvement of the mucosa. In the same series reported by Jensen, 9 tumors were found in the ischioanal space, 7 were found in the anal canal, and 5 were seen in a fistula.5 With the variable nature of the glandular mucosa, the pathology of glandular cancer may be an adenocarcinoma or squamous cancer.

Because there are so few reported cases of anal adenocarcinoma, uniform treatment recommendations based on solid data are difficult to obtain. It is clear that treatment results are relatively poor and this disease seems to be much more aggressive than its anal squamous cell counterpart when matched for local recurrence rates and survival rates.

Treatment regimens have included wide local excision (WLE), abdomin perineal resection (APR), radiation, chemoradiation, and combined modality therapy, usually pre- or postoperative chemoradiation and an APR. WLE may be possible in small tumors of the proximal anal canal. The tumors must be mobile, well differentiated, and should not invade the sphincters. These types of tumors are rare.

In a large multicenter study by Belkacemi,6 82 patients with anal canal adenocarcinoma were evaluated for treatment results. The 3 treatment groups consisted of radiotherapy with surgical extirpation, chemoradiation, or an APR. The 5-year survival and disease-free survival (DFS) rates were best in the chemoradiation group. Five and 10-year overall survival rates were 58% and 39%, respectively. Disease-free rates at 5 and 10 years were 54% and 20%, respectively. Additionally, the authors concluded that an APR should be reserved for salvage. The independent predictors of survival were T stage, N stage, histologic grade, and...
Melanoma

Anal melanoma is an ominous tumor. Fortunately, it also is a rare tumor. Fewer than 500 cases have been reported, and it constitutes between 0.5% and 5% of all anal malignancies. Melanoma of the anal canal is the third most common site of occurrence after skin and ocular melanoma. Patients with anal melanoma are white females with an average age of 63 years. The disease rarely is reported in the black or Asian populations. Women are twice as likely as men to have this lesion. Although the etiology is unknown, one report of 117 cases detailed a tripling of the incidence of the disease in males younger than 44 years of age in San Francisco when compared with other geographic locations. Women are twice as likely as men to have this lesion. Although the etiology is unknown, one report of 117 cases detailed a tripling of the incidence of the disease in males younger than 44 years of age in San Francisco when compared with other geographic locations (14.4 vs. 4.8 per 10 million population). In this study, the male-to-female ratio was 1.17. With an average age at diagnosis of 57 years for men and 71 years for women. Men had a survival advantage over women at 1 and 2 years (62.8% vs 51.4% at 1 year, and 40.6% vs 27.7% at 2 years, respectively). This new bimodal trend was noted and HIV was suggested as a risk factor.

The lesion may arise at any location in the anal canal. Bleeding is the usual patient complaint, followed by pain. Altered bowel habits and tenesmus also are reported. Weight loss is common. The most common presenting sign is an anal mass. Seventy-five percent of patients have a mass greater than 1 cm, and the average diameter is 4 cm. Many patients have associated involved inguinal lymph nodes.

Anal melanoma often is confused with a thrombosed hemorrhoid. Larger lesions may be polypoid and ulcerated, distinguishing the lesion from a thrombotic hemorrhoid (Figure 2). In one study, 71% of patients had “gross and/or histologic pigmentation,” whereas other studies have found these lesions to be amelanotic in 41% of cases. If melanin is seen on microscopic examination, the diagnosis is straightforward. In the amelanotic form, the presence of “malignant cells in clusters” helps to differentiate this lesion from an undifferentiated squamous cell carcinoma.

Thirty-eight percent of patients had either metastatic nodal involvement (perirectal, perianal, and mesenteric nodes, followed by inguinal node disease) or distant metastases to the liver and lung. Between 38% and 62% of patients presented initially with metastatic disease to lymph nodes, and not uncommonly to distant sites as well. Submucosal spread is common.

Although there are conflicting issues in trying to choose a treatment modality and predict survival rates using various parameters, one point is clear: 5-year survival rates are dismal. Survival rates range between 0% and 29%. As many as 35% of patients have metastatic disease at the time of presentation, and one study showed that in patients whose
tumors are thicker than 10 mm, cure is not possible.  

In a review of the Mayo Clinic experience, no single factor predicted survival. Factors evaluated were gender, size of the lesion, presence of melanin, depth of penetration, positive perirectal lymph nodes and WLE versus APR.  

Interestingly, the Memorial Sloan-Kettering (MSK) series found that the only long-term survivors were women.  

Available surgical options include wide local excision or abdominoperineal resection. In MSK and Mayo Clinic series, overall 5-year survival rates were 17% and 22%, respectively, and were unrelated to the type of surgical procedure used to extirpate the disease. However, the MSK series of 85 patients suggested that 5-year DFS using an "APR was more favorable than that of patients who underwent local procedures only, although this was not statistically significant (27% vs 5%, APR vs local procedures, respectively; P=0.11)." This report concluded that an APR should be used in those patients with localized anorectal melanomas and no evidence of nodal disease. However, the Mayo Clinic series of 50 patients found 5-year survival and recurrence rates to be the same after curative WLE or APR, but concluded that "wide local excision with a negative margin of at least 1 cm is suggested as the treatment of choice. APR should be reserved for tumor not amenable to local excision or for palliative treatment of large obstructive lesion [sic] until effective adjuvant therapies are available."  

One study examined tumor thickness, comparing anorectal melanoma to cutaneous melanomas in an attempt to formulate guidelines for treatment. The study recommended WLE with a 1 cm margin of normal tissue for tumors less than 1 mm in thickness, and WLE with a 2 cm margin of normal tissue in tumors between 1 and 4 mm in thickness, as long as the internal sphincter was tumor-free; an APR was recommended for all other tumors.  

Most authors note that with documented regional metastatic disease or distal metastases, patients should be spared an APR and permanent colostomy, as long-term survival rates are almost nonexistent. However, in those patients with bulky tumors, or in patients in whom the surgeon is unable to obtain 1- to 2-cm tumor-free margins with a WLE, or in patients with tumor involvement of the anal sphincter, or in those patients who would be rendered incontinent after a WLE, an APR may be the treatment of choice.  

Numerous immunologic and adjuvant chemotherapeutic treatments have been tried with little benefit in patients with anorectal melanoma. Radiation therapy is of proven benefit as well. Local control, although possible with surgical treatment, often is useless, as distant metastatic disease is a major cause of death.  

Neuroendocrine Carcinomas  

Also called a small cell carcinoma, a large cell neuroendocrine tumor, or a Merkel cell carcinoma, this tumor is so named because it is derived from cells of both the endocrine system and the nervous system. Neuroendocrine cells are found in many organ systems and tissues, with the gastrointestinal tract harboring the largest volumes of these cells. These tumors are rare, comprising less than 1% of all lower digestive tract cancers. Most neuroendocrine tumors are found in the rectum and cecum.  

In a study from the MSK Cancer Center of 6,495 patients with colorectal cancer over a 23-year period, 6 neuroendocrine tumors, representing less than 0.1% of all colorectal malignancies, were found in the anal canal.  

Colorectal neuroendocrine tumors are classified as either low-grade carcinoids or high-grade neuroendocrine carcinomas. The neuroendocrine lesions can be further subdivided into small cell carcinomas or large cell neuroendocrine carcinomas. All of these high-grade neuroendocrine tumors have at least 50% of the tumor demonstrating typical neuroendocrine characteristics. “These features include a densely cellular, solid growth pattern, with cells arranged in nests having minimal intercellular stroma.” There is no gland formation. There are features of necrosis and a mitotic rate “of greater than 10 per high-power” field on microscopy. Based on cytological features, further subdivision into small cell carcinoma or large cell neuroendocrine carcinomas is possible, with the small cell form resembling the pulmonary form of small cell cancer. This division into small and large cell forms resembles the classification of pulmonary neuroendocrine tumors.  

The small cell carcinoma does not require immunohistochemical documentation and may be diagnosed solely by hematoxylin and eosin microscopy. The large cell variant does require immunohistochemical documentation, with the finding of at least 1 of 3 neuroendocrine markers (chromogranin, synaptophysin, and neuron-specific enolase) in at least 10% of the tumor cells.  

In the MSK study, 80% of all neuroendocrine tumors stained positive immunohistochemically for neuroendocrine markers and most presented at an advanced stage, although no mention was made as to the specific stage of presentation seen in anal lesions.  

Diagnosis involves a high index of suspicion in patients with any type of anorectal complaint. An obvious lesion removed surgically will then be submitted for the appropriate microscopic and immunohistochemical evaluation.  

As these tumors are rare, no single series can reliably evaluate the different modes of available treatment and survival. Patients have been treated with excision, radical extirpative procedures with or without adjuvant therapy, radiation alone, or chemotherapy alone. Staging is important, as up to 85% of extrapulmonary small cell tumors in one series presented with metastatic disease not amenable to surgical cure. Small cell variants with documented metastatic spread can be treated like pulmonary tumors, with cisplatin and etoposide. Other chemotherapeutic regimens including cyclophosphamide, doxorubicin, and vincristine have been used in treatment protocols. The success of chemotherapeutic treatment of anal lesions has not been verified.  

Although not validated, it would make sense to treat patients with disease limited to the anal canal with extirpative surgery and/or chemoradiation, akin to the treatment for anal adenocarcinoma. In the study by Bernick et al., looking at all treatment modalities in 36 patients who completed treatment and follow-up, median survival was 10.5 months, with an overall disease-specific median survival of 16 months.  

Small cell carcinomas and large cell neuroendocrine carcinomas demonstrated similar survival curves. One-year, 2-year and 3-year survival rates were 46%, 26%, and 13%, respectively. These are aggressive tumors and are difficult to treat. The best that can be said of them is that they are rare.  

References  

4. Wolf BG, Flesham JW, Beck DF, Pemberton JH, Wexner SD. The ASCRS Textbook of Colon and Rectal Surgery. California, Los Angeles. He is a senior clinical professor of surgery at the David Geffen School of Medicine, University of California, Los Angeles. He is a senior member of Los Angeles Colon and Rectal Surgical Associates (www.lacolon.com).

—Dr. Hoffman is attending surgeon and instructor in the Division of Colorectal Surgery at Cedars-Sinai Medical Center, and attending surgeon in the Division of General Surgery and associate clinical professor of surgery at the David Geffen School of Medicine, University of California, Los Angeles. He is a senior member of Los Angeles Colon and Rectal Surgical Associates (www.lacolon.com).